Evidence map›Paper›PMID 29872177›Full record

ReviewNature reviews. Clinical oncology2018

Safety of combining radiotherapy with immune-checkpoint inhibition.

William L Hwang, Luke R G Pike, Trevor J Royce, Brandon A Mahal, Jay S Loeffler

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03864211 (Phase I/II Study of Thermal Ablation Followed by Toripalimab in Unresectable Hepatocellular Carcinoma), which is not on this map. Cited by 168 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
168citing papers in PubMed, 6 pooled it
12.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03864211 phase1 / phase2unknown statusnot on this mapstarted 2019, after this paper: background citation

Phase I/II Study of Thermal Ablation Followed by Toripalimab in Unresectable Hepatocellular Carcinoma

TypeinterventionalSponsorXiangya Hospital of Central South UniversityRan2019 to 2023Enrolled145ConditionsHepatocellular Carcinoma Non-resectableArmsThermal ablation, Toripalimab
3 · Its place in the literature

Who cites it

168 citing papers in PubMed, 6 syntheses or guidelines pooled it, 283 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Longitudinally Extensive Myelitis Associated With Immune Checkpoint Inhibitors.Neurology(R) neuroimmunology & neuroinflammation · 2021
    Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

108 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

William L HwangHarvard Radiation Oncology Program, Harvard Medical School, Boston, MA, USA.
Luke R G PikeHarvard Radiation Oncology Program, Harvard Medical School, Boston, MA, USA.
Trevor J RoyceHarvard Radiation Oncology Program, Harvard Medical School, Boston, MA, USA.
Brandon A MahalHarvard Radiation Oncology Program, Harvard Medical School, Boston, MA, USA.
Jay S LoefflerDepartment of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA. jloeffler@mgh.harvard.edu.
Massachusetts General Hospital · USHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune-checkpoint inhibitors targeting cytotoxic T- lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), or programmed cell death 1 ligand 1 (PD-L1) have transformed the care of patients with a wide range of advanced-stage malignancies. More than half of these patients will also have an indication for treatment with radiotherapy. The effects of both radiotherapy and immune-checkpoint inhibition (ICI) involve a complex interplay with the innate and adaptive immune systems, and accumulating evidence suggests that, under certain circumstances, the effects of radiotherapy synergize with those of ICI to augment the antitumour responses typically observed with either modality alone and thus improve clinical outcomes. However, the mechanisms by which radiotherapy and immune-checkpoint inhibitors synergistically modulate the immune response might also affect both the type and severity of treatment-related toxicities. Moreover, in patients receiving immune-checkpoint inhibitors, the development of immune-related adverse events has been linked with superior treatment responses and patient survival durations, suggesting a relationship between the antitumour and adverse autoimmune effects of these agents. In this Review, we discuss the emerging data on toxicity profiles related to immune-checkpoint inhibitors and radiotherapy, both separately and in combination, their potential mechanisms, and the approaches to managing these toxicities.

Indexed as

B7-H1 AntigenCombined Modality TherapyCTLA-4 AntigenDrug-Related Side Effects and Adverse ReactionsHumansImmunotherapyNeoplasmsProgrammed Cell Death 1 ReceptorB7-H1 AntigenCD274 protein, humanCTLA-4 AntigenPDCD1 protein, humanProgrammed Cell Death 1 Receptor

Identifiers

PMID29872177
OpenAlexW2805209851

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.